ArticleCurrent oncology (Toronto, Ont.)2025

Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer.

Zhan Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.